Pre-made Foravirumab benchmark antibody ( Whole mAb, anti-RV Antigenic Site III therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-221

Pre-Made Foravirumab biosimilar, Whole Mab: Anti-RV Antigenic Site III therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Foravirumab is a monoclonal antibody for the prophylaxis of rabies. It is under development by Sanofi/Crucell.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-221-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Foravirumab biosimilar, Whole Mab: Anti-RV Antigenic Site III therapeutic antibody
INN Name Foravirumab
TargetRV Antigenic Site III
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesCrucell;Sanofi Pasteur
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedRabies
Development TechHuman Phage Display